David DMS - LumiraDx Chief Officer

LMDXDelisted Stock  USD 0.42  0.02  4.55%   

Insider

David DMS is Chief Officer of LumiraDx
Age 70
Phone44 11 7284 2535
Webhttps://www.lumiradx.com

LumiraDx Management Efficiency

The company has return on total asset (ROA) of (0.2804) % which means that it has lost $0.2804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.6448) %, meaning that it created substantial loss on money invested by shareholders. LumiraDx's management efficiency ratios could be used to measure how well LumiraDx manages its routine affairs as well as how well it operates its assets and liabilities.
LumiraDx currently holds 401.25 M in liabilities. LumiraDx has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about LumiraDx's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jinxiang LiBurning Rock Biotech
39
Steven GravesSera Prognostics
N/A
Matt StaufferBiodesix
N/A
Sean MDSera Prognostics
N/A
Shaokun ChuaiBurning Rock Biotech
45
Debra ZackExagen Inc
65
Kristin GibbsSotera Health Co
N/A
Nadia AltomareSera Prognostics
53
Dieter MDEnzo Biochem
61
Zvi DavidDarioHealth Corp
63
Rebecca FischerEnzo Biochem
52
Lehmann JDSotera Health Co
56
Dov OppenheimDarioHealth Corp
N/A
Heinrich RderBiodesix
N/A
MingChou LeeExagen Inc
N/A
Peter ClemensEnzo Biochem
N/A
Mark HazeltineExagen Inc
50
Jeffrey BojarBiodesix
N/A
Robert HauzieSotera Health Co
N/A
Robert HarrisonSera Prognostics
58
Ryan SiurekBiodesix
52
LumiraDx Limited operates as a point of care diagnostics company. The company was founded in 2014 and is headquartered in London, the United Kingdom. Lumiradx is traded on NASDAQ Exchange in the United States. LumiraDx (LMDX) is traded on NASDAQ Exchange in USA and employs 1,210 people.

Management Performance

LumiraDx Leadership Team

Elected by the shareholders, the LumiraDx's board of directors comprises two types of representatives: LumiraDx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LumiraDx. The board's role is to monitor LumiraDx's management team and ensure that shareholders' interests are well served. LumiraDx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LumiraDx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Colleen McMillen, VP Communications
Jerome McAleer, Chief CoFounder
David DMS, Chief Officer
Dorian CPA, CFO Operations
Nigel Lindner, Chief Officer
David Scott, CTO CoFounder
Peter Scheu, Pres Operations
Ron Zwanziger, Chairman CoFounder
Andy Ward, National UK
Veronique Ameye, Exec Counsel

LumiraDx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LumiraDx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in LumiraDx Stock

If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios